6533b825fe1ef96bd1282e8f

RESEARCH PRODUCT

“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”

P ComellaB MassiddaD NataleG FilippelliA FarrisG CondemiS TafutoG VessiaG BarberisC. SandomenicoSergio Palmeri

subject

Settore MED/06 - Oncologia Medicabevacizumab metastatic colorectal cancerhttp://hdl.handle.net/10447/45336